{"result": {"id": "6a8c834f-869d-4538-8096-917fee1861eb", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"Hypertension Research and Clinical Trials Community\",\n    \"summary\": \"This community is centered around key entities involved in hypertension research and clinical trials, including the VALUE TRIAL, FRAMINGHAM HEART STUDY, SPRINT RESEARCH GROUP, and various professional societies like the FRENCH SOCIETY OF HYPERTENSION and CHINESE SOCIETY OF HYPERTENSION. These entities are interconnected through their focus on hypertension management, cardiovascular disease risk factors, and the publication of influential studies and guidelines. The community's impact is significant due to its contributions to understanding and managing hypertension, a major global health issue.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the community's pivotal role in advancing hypertension research and influencing clinical guidelines worldwide.\",\n    \"findings\": [\n        {\n            \"summary\": \"Central Role of VALUE TRIAL and FRAMINGHAM HEART STUDY\",\n            \"explanation\": \"The VALUE TRIAL and FRAMINGHAM HEART STUDY are central to this community, with both investigating the effects of blood pressure on cardiovascular events. Their research provides critical insights into hypertension management and cardiovascular disease prevention. [Data: Entities (1346, 1347), Relationships (4687)]\"\n        },\n        {\n            \"summary\": \"Influence of SPRINT RESEARCH GROUP\",\n            \"explanation\": \"The SPRINT RESEARCH GROUP's landmark trial on blood pressure control has significantly influenced clinical guidelines, showcasing the group's pivotal role in hypertension research. [Data: Entities (1369), Relationships (1146, 1149)]\"\n        },\n        {\n            \"summary\": \"Collaboration Between Professional Societies\",\n            \"explanation\": \"Professional societies such as the FRENCH SOCIETY OF HYPERTENSION and CHINESE SOCIETY OF HYPERTENSION collaborate on hypertension research and guidelines, highlighting the global effort to address hypertension. [Data: Entities (1371, 1372), Relationships (1153)]\"\n        },\n        {\n            \"summary\": \"Publication in Prestigious Journals\",\n            \"explanation\": \"Key studies, including the SPRINT trial, have been published in the NEW ENGLAND JOURNAL OF MEDICINE, underscoring the community's contribution to high-impact medical research. [Data: Entities (1374), Relationships (1149)]\"\n        },\n        {\n            \"summary\": \"Expert Contributions to Hypertension Consensus\",\n            \"explanation\": \"Experts like WRIGHT JT and DENOLLE T have contributed significantly to hypertension research and consensus statements, demonstrating the community's depth of expertise. [Data: Entities (1379, 1385), Relationships (1150, 1154)]\"\n        }\n    ]\n}", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752169011, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 567, "prompt_tokens": 4999, "total_tokens": 5566, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1856}, "prompt_cache_hit_tokens": 1856, "prompt_cache_miss_tokens": 3143}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        },\n        {\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        },\n        {\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        },\n        {\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }\n    ]\n}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n1346,VALUE TRIAL,\"The **VALUE TRIAL** is a clinical study focused on investigating both the **blood pressure-dependent and blood pressure-independent effects** of antihypertensive treatment on clinical outcomes. The trial aims to assess how these treatments influence medical events, examining whether their benefits stem directly from blood pressure reduction or from other underlying mechanisms.  \n\nBoth provided descriptions align in their core objective, emphasizing the dual focus on blood pressure-related and unrelated impacts of antihypertensive therapies. The study seeks to clarify the broader clinical implications of such treatments beyond mere blood pressure control.  \n\nIn summary, the **VALUE TRIAL** is a research initiative designed to evaluate the multifaceted effects of antihypertensive interventions, distinguishing between outcomes directly tied to blood pressure changes and those arising from alternative pathways. The trial's findings could enhance understanding of optimal treatment strategies for hypertension and related conditions.  \n\n*(Word count: 149)*\",4\r\n1347,FRAMINGHAM HEART STUDY,\"The **Framingham Heart Study** is a long-term research project focused on investigating cardiovascular disease (CVD) risk factors, conducted in the town of Framingham. One of its key areas of examination involves analyzing the relationship between blood pressure components—both individually and in combination—and their association with cardiovascular disease risk. The study explores whether single blood pressure metrics (such as systolic or diastolic pressure) or combined measurements provide stronger predictive value for CVD outcomes. By evaluating these factors, the Framingham Heart Study contributes to a deeper understanding of how blood pressure influences cardiovascular health, aiding in the development of more effective risk assessment and prevention strategies. The research underscores the study's broader mission to identify and clarify critical determinants of heart disease.\",6\r\n1368,AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION TASK FORCE,Task force responsible for expert consensus documents on hypertension in the elderly>,4\r\n1369,SPRINT RESEARCH GROUP,\"The **SPRINT RESEARCH GROUP** conducted a randomized trial comparing intensive versus standard blood-pressure control. The study aimed to evaluate the effects of more aggressive blood-pressure management compared to conventional approaches, though the exact outcomes or specific details of the trial are not provided in the descriptions. Both descriptions are consistent, reinforcing that the group's primary focus in this context was on investigating differing blood-pressure control strategies. The study likely contributed to broader medical research on hypertension management, though further details would be needed to elaborate on its findings or significance.  \n\n(Note: The descriptions provided were nearly identical, so no contradictions required resolution. The summary consolidates the information while maintaining clarity and context.)\",5\r\n1371,FRENCH SOCIETY OF HYPERTENSION,\"The **French Society of Hypertension** is an affiliate of the **French Society of Cardiology** and has played a significant role in advancing clinical understanding and management of hypertension. Notably, the society has issued expert consensus guidelines on **resistant hypertension**, contributing to standardized approaches in diagnosis and treatment. Both provided descriptions emphasize its affiliation with the French Society of Cardiology and its authoritative work in formulating consensus statements on this challenging condition. The descriptions are consistent, reinforcing the society's collaborative ties and its focus on addressing complex hypertensive disorders.  \n\nIn summary, the **French Society of Hypertension** operates under the umbrella of the **French Society of Cardiology** and is recognized for its expert-led consensus on resistant hypertension, underscoring its commitment to improving hypertension care through evidence-based recommendations.\",5\r\n1372,CHINESE SOCIETY OF HYPERTENSION,\"The **Chinese Society of Hypertension** is a professional organization dedicated to addressing hypertension-related issues, including the management of resistant hypertension. The society has issued official positions and recommendations on the use of **renal denervation** as a treatment for resistant hypertension, providing guidance to healthcare professionals on its application and efficacy. By consolidating expert opinions and evidence-based research, the society plays a key role in advancing clinical practices and improving patient outcomes in this specialized area of cardiovascular care.  \n\nThe organization's recommendations on renal denervation reflect its commitment to exploring innovative therapeutic approaches for challenging cases of hypertension. These guidelines serve as a reference for physicians and researchers, ensuring standardized and informed decision-making in the treatment of resistant hypertension. Through its work, the **Chinese Society of Hypertension** contributes to the broader medical community by promoting best practices and fostering advancements in hypertension management.\",4\r\n1374,NEW ENGLAND JOURNAL OF MEDICINE,\"The *New England Journal of Medicine (NEJM)* is a prestigious medical journal known for publishing high-impact clinical studies and research. Among its notable publications is the **SPRINT trial**, a landmark study on blood pressure control that significantly influenced clinical guidelines. Additionally, NEJM has featured research on emerging therapies, including studies on **evinacumab**, an investigational drug for lipid management, and **volanesorsen**, a treatment targeting metabolic disorders. By disseminating cutting-edge medical research, NEJM plays a critical role in advancing evidence-based medicine and shaping healthcare practices worldwide.  \n\n(Word count: 94)\",3\r\n1359,FRANKLIN SS,\"Researcher involved in the Framingham Heart Study\"\"\",1\r\n1360,LOPEZ VA,\"Researcher involved in the Framingham Heart Study\"\"\",1\r\n1361,WONG ND,\"Researcher involved in the Framingham Heart Study\"\"\",1\r\n1001,CHINESE PHYSICIAN ASSOCIATION EMERGENCY PHYSICIAN BRANCH,\"A branch of the Chinese Physician Association focused on emergency medicine\"\"\",3\r\n1379,WRIGHT JT,\"**WRIGHT JT** is a prominent researcher known for his significant involvement in the **SPRINT (Systolic Blood Pressure Intervention Trial) blood pressure trial**. He served as the **lead investigator** for the **SPRINT Research Group**, playing a pivotal role in overseeing and directing the study. The SPRINT trial was a landmark clinical investigation focused on evaluating intensive blood pressure management strategies and their impact on cardiovascular outcomes. As the lead investigator, WRIGHT JT was instrumental in guiding the research design, implementation, and analysis of the trial's findings. His leadership and expertise contributed to the trial's influential results, which have had lasting implications for hypertension treatment guidelines. WRIGHT JT's work underscores his dedication to advancing cardiovascular research and improving patient care in the field of hypertension.\",1\r\n1380,WILLIAMSON JD,Researcher involved in the SPRINT blood pressure trial>,1\r\n1385,DENOLLE T,Author of French hypertension consensus statement>,1\r\n4495,DENERV,A study comparing spironolactone and sympathetic renal denervation for resistant hypertension>,1\r\n4496,AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION,Published expert consensus on hypertension in the elderly>,1\r\n1000,CHINESE PHYSICIAN ASSOCIATION RESPIRATORY PHYSICIAN BRANCH,\"A branch of the Chinese Physician Association focused on respiratory medicine\"\"\",2\r\n1005,CHINESE PHYSICIAN ASSOCIATION,\"A professional association for physicians in China\"\"\",2\r\n1343,WEBER MA,\"**WEBER MA** is a researcher who was involved in the **VALUE Trial**, a clinical study focused on evaluating cardiovascular outcomes. The descriptions consistently highlight his participation in this trial, indicating his role as a key contributor to the research. No contradictory information was provided, confirming his association with the VALUE Trial.  \n\n(Note: The two descriptions are identical, so the summary is concise and unambiguous.)\",1\r\n1344,JULIUS S,\"Researcher involved in the VALUE Trial\"\"\",1\r\n1345,KJELDSEN SE,\"Researcher involved in the VALUE Trial\"\"\",1\r\n1381,ARONOW WS,Expert contributor to ACCF/AHA hypertension consensus>,1\r\n1382,FLEG JL,Expert contributor to ACCF/AHA hypertension consensus>,1\r\n4501,BEIJING HYPERTENSION PREVENTION ASSOCIATION,\"An organization involved in developing hypertension treatment consensus in China\"\"\",1\r\n4814,RAAL FJ,\"Researcher involved in a study on evinacumab for homozygous familial hypercholesterolemia\"\"\",3\r\n4815,ROSENSON RS,\"Researcher involved in a study on evinacumab for homozygous familial hypercholesterolemia\"\"\",2\r\n4816,REESKAMP LF,\"Researcher involved in a study on evinacumab for homozygous familial hypercholesterolemia\"\"\",2\r\n4817,WITZTUM JL,\"Researcher involved in a study on volanesorsen and triglyceride levels in familial chylomicronemia syndrome\"\"\",3\r\n4818,GAUDET D,\"Researcher involved in a study on volanesorsen and triglyceride levels in familial chylomicronemia syndrome\"\"\",2\r\n4819,FREEDMAN SD,\"Researcher involved in a study on volanesorsen and triglyceride levels in familial chylomicronemia syndrome\"\"\",2\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\r\n4687,VALUE TRIAL,FRAMINGHAM HEART STUDY,Both investigate blood pressure effects on cardiovascular events,10\r\n1146,AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION TASK FORCE,SPRINT RESEARCH GROUP,Both conducted studies on hypertension management,9\r\n1153,FRENCH SOCIETY OF HYPERTENSION,CHINESE SOCIETY OF HYPERTENSION,Both societies focus on hypertension research and guidelines,9\r\n1149,SPRINT RESEARCH GROUP,NEW ENGLAND JOURNAL OF MEDICINE,SPRINT trial was published in NEJM,8\r\n1135,FRAMINGHAM HEART STUDY,FRANKLIN SS,Franklin SS was involved in the Framingham Heart Study,7\r\n1136,FRAMINGHAM HEART STUDY,LOPEZ VA,Lopez VA was involved in the Framingham Heart Study,7\r\n1137,FRAMINGHAM HEART STUDY,WONG ND,Wong ND was involved in the Framingham Heart Study,7\r\n4699,CHINESE SOCIETY OF HYPERTENSION,CHINESE PHYSICIAN ASSOCIATION EMERGENCY PHYSICIAN BRANCH,Collaborated on the 2017 Chinese Emergency Hypertension Diagnosis and Treatment Expert Consensus,7\r\n1150,SPRINT RESEARCH GROUP,WRIGHT JT,\"**SPRINT RESEARCH GROUP & WRIGHT JT**  \n\nWright JT (Jackson T. Wright Jr.) was a prominent lead researcher in the SPRINT (Systolic Blood Pressure Intervention Trial) Research Group, where he played a pivotal role in directing the study. As a key figure in the trial, Wright JT contributed to its design, execution, and findings, which focused on evaluating intensive blood pressure management strategies. His leadership was instrumental in advancing the research objectives of the SPRINT trial, a landmark study in cardiovascular and hypertension research. The descriptions consistently highlight his central involvement, reinforcing his position as a leading investigator within the SPRINT Research Group.  \n\n(Word count: 98)\",6\r\n1151,SPRINT RESEARCH GROUP,WILLIAMSON JD,Williamson was a lead researcher in the SPRINT trial,6\r\n1154,FRENCH SOCIETY OF HYPERTENSION,DENOLLE T,Denolle authored the society's consensus statement,6\r\n4690,FRENCH SOCIETY OF HYPERTENSION,DENERV,DENERV study aligns with the Society's focus on resistant hypertension,6\r\n4691,FRENCH SOCIETY OF HYPERTENSION,AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION,Both produce hypertension treatment guidelines,6\r\n792,CHINESE PHYSICIAN ASSOCIATION RESPIRATORY PHYSICIAN BRANCH,CHINESE PHYSICIAN ASSOCIATION EMERGENCY PHYSICIAN BRANCH,Both are branches of the Chinese Physician Association,5\r\n794,CHINESE PHYSICIAN ASSOCIATION EMERGENCY PHYSICIAN BRANCH,CHINESE PHYSICIAN ASSOCIATION,The emergency branch is part of the Chinese Physician Association,5\r\n1132,WEBER MA,VALUE TRIAL,Weber MA was involved in the VALUE Trial,5\r\n1133,JULIUS S,VALUE TRIAL,Julius S was involved in the VALUE Trial,5\r\n1134,KJELDSEN SE,VALUE TRIAL,Kjeldsen SE was involved in the VALUE Trial,5\r\n1147,AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION TASK FORCE,ARONOW WS,Aronow contributed to ACCF/AHA consensus documents,5\r\n1148,AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION TASK FORCE,FLEG JL,Fleg contributed to ACCF/AHA consensus documents,5\r\n4700,CHINESE SOCIETY OF HYPERTENSION,BEIJING HYPERTENSION PREVENTION ASSOCIATION,Collaborated on hypertension treatment guidelines,5\r\n5060,RAAL FJ,ROSENSON RS,Both researchers were involved in the same study on evinacumab for homozygous familial hypercholesterolemia,5\r\n5061,RAAL FJ,REESKAMP LF,Both researchers were involved in the same study on evinacumab for homozygous familial hypercholesterolemia,5\r\n5064,WITZTUM JL,GAUDET D,Both researchers were involved in the same study on volanesorsen and triglyceride levels in familial chylomicronemia syndrome,5\r\n5065,WITZTUM JL,FREEDMAN SD,Both researchers were involved in the same study on volanesorsen and triglyceride levels in familial chylomicronemia syndrome,5\r\n793,CHINESE PHYSICIAN ASSOCIATION RESPIRATORY PHYSICIAN BRANCH,CHINESE PHYSICIAN ASSOCIATION,The respiratory branch is part of the Chinese Physician Association,4\r\n5063,ROSENSON RS,REESKAMP LF,Both researchers were involved in the same study on evinacumab for homozygous familial hypercholesterolemia,4\r\n5067,GAUDET D,FREEDMAN SD,Both researchers were involved in the same study on volanesorsen and triglyceride levels in familial chylomicronemia syndrome,4\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_36c3451c3841ea7236c6237a690528fbb40e61389e09a6fc44448cad792fcf0f_v2"}